5th Drug Formulation & Bioavailability

Most of the drugs and APIs currently on the market are poorly water-soluble and need to have their bioavailability improved through the development of enabled formulations and patient-centric delivery mechanisms. Despite the promises of many “next generation” techniques, the biopharma industry continues to rely on refinements to amorphous solid dispersions and hot melt extrusions. Formulation professionals will continue to face challenges in the solubility and characterization of these drug delivery methods for years to come.

Now in its fifth year, the Drug Formulation, Solubility and Bioavailability conference is geared toward improving drug performance and therapeutic impact through enabled formulations and more effective delivery methods.

Top Five Reasons to Attend

1. More than 30 speakers and eight hours of networking in a three-day program, featuring experts from AbbVie, Amgen, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Ferring, Genentech, GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Novartis, and many other organizations
2. Optimal techniques to increase dose loading in early stages when little drug material is available
3. Special emphasis on how to select the ideal excipients for both small molecules and biologics
4. A road map for improving drug characterization techniques without getting swamped by an overabundance of data
5. In-depth insights on the latest advances in subcutaneous, inhalation, oral and ocular drug delivery methods